← All indications
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Subtype terms (5)
More specific conditions that are subtypes of Lymphoma, Non-Hodgkin in the MeSH hierarchy.
- Lymphoma, B-Cell
334 drugs (123 approved, 211 experimental)
- Lymphoma, Follicular
370 drugs (147 approved, 223 experimental)
- Lymphoma, Large-Cell, Immunoblastic
321 drugs (159 approved, 162 experimental)
- Lymphoma, Mantle-Cell
341 drugs (137 approved, 204 experimental)
- Lymphoma, T-Cell
274 drugs (126 approved, 148 experimental)
Drugs by status
Approved for this indication (16)
Phase 4 trials (27)
- entecavir
- fludarabine
- vincristine
- dexamethasone
- Filgrastim
- sargramostim
- temsirolimus
- lidocaine
- pirtobrutinib
- cytarabine
- 23-valent pneumococcal polysaccharide vaccine
- ceftazidime
- palifermin
- carboplatin
- idarubicin
- melphalan
- ibrutinib
- valsartan
- cyclophosphamide
- ciprofloxacin
- prilocaine
- tenofovir
- ifosfamide
- epirubicin
- prednisone
- etoposide
- methotrexate
Phase 3 trials (87)
- moxifloxacin
- autologous umbilical cord blood
- thiotepa
- cycloheximide
- fnhlid1
- vindesine
- inotuzumab ozogamicin
- bnt162b2
- nktr-255
- valganciclovir
- mosunetuzumab
- venetoclax
- muromonab cd3
- tumor-pulsed dendritic cells
- urea
- cisplatin
- paclitaxel
- pixuvri
- vinorelbine
- Anti-thymocyte Globulin (Rabbit)
- gemcitabine
- sirolimus
- oxaliplatin
- mrna-1273
- metronidazole
- vitamin d3
- jcar017
- brentuximab vedotin
- lenalidomide
- amoxicillin
- +57 more
Phase 2 trials (361)
- sodium chloride
- 1928t2z car-t cell
- ctx110
- gen3009
- topotecan
- palbociclib
- Epcoritamab
- mercaptopurine
- lysergic acid diethylamide
- rqr8/atrbc1 car t
- Chiauranib
- nogapendekin alfa inbakicept
- poly-iclc
- relatlimab
- avadomide
- tislelizumab
- tegavivint
- js203
- autologous lymphocytes
- dasatinib
- vismodegib
- msk-2206
- nemtabrutinib
- trac and power3 genes knock-out allogeneic cd19-targeting car-t cell
- tak-981
- dimethylarsinous glutathione
- oblimersen sodium
- wtx-330
- cerdulatinib
- TNB-486
- +331 more
Phase 1 trials (365)
- peripheral blood lymphocytes
- Trotabresib
- zn-d5
- apg-5918
- kw-2478
- cc-90011
- tr115
- ono-7018
- car.k.28
- amg-319
- bgb-16673
- aprepitant
- ct-rd06
- cdx-1140
- cosibelimab
- dinaciclib
- hiv-1 specific car-t cells
- ketoconazole
- capecitabine
- cefepime
- nilotinib
- mdx-1203
- anti-cd19 fast car-t cells
- cnty-101
- jnj-87801493
- sirpant-m
- ace1831
- cd7.car/28zeta car t cell
- mik665
- sgn-75
- +335 more
Other trials (30)
- avm0703
- lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells
- metoclopramide
- autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
- et-02
- zidovudine
- bexarotene
- chia seed
- jcxh-213
- triamcinolone
- tetanus toxoid
- foscarnet
- deferasirox
- lithium
- auto car-t
- dendritic cell tumor fusion vaccine
- cu-64 rituximab
- cd8 depleted donor lymphocyte
- ganciclovir
- anti-cd19/20-car vector-transduced t cells
- fialuridine
- prochlorperazine
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- graviola
- brl-301
- buparlisib
- hydrocortisone
- 68ga-dotanoc
- jy231
- lorazepam
Organizations
Organization Involved with Phase 4 Indications (27)
- Tsinghua University
- Chinese Academy of Medical Sciences
- Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon
- Zhejiang University
- Biovitrum AB
- Peking University
- Anhui Medical University
- J. W. Goethe University
- Pfizer
- Roche
- Shandong Provincial Hospital
- Taipei Veteran General hospital
- Seoul National University
- Millennium Pharmaceuticals
- Tel Aviv University
- Asociacion Espanola de Hematologia y Hemoterapia
- People's Liberation Army of China
- University of Bologna
- Osaka City University
- Biogen
- Jiao Tong University
- Swedish Orphan Biovitrum
- Zhengzhou University
- Federal University of Minas Gerais
- Bristol-Myers Squibb
- Konkuk University
- Pharmacyclics
Organization Involved with Phase 3 Indications (123)
- Verastem, Inc.
- National Center for Research Resources (NCRR)
- Gruppo Italiano Studio Linfomi
- Schering-Plough
- BeOne Medicines
- Peter MacCallum Cancer Centre
- Deutsche Krebshilfe e.V.
- University of California, San Francisco
- University of Lyon
- Free University of Amsterdam
- German Low Grade Lymphoma Study Group
- National Heart, Lung, and Blood Institute (NHLBI)
- Children Oncology Group, USA
- Free University of Brussels
- British Columbia Cancer Agency
- Utrecht University
- Bayer
- Southwest Oncology Group
- Biovest International
- Sanofi
- The Lymphoma Study Association
- Genitope Corporation
- Cancer and Leukemia Group B (CALGB)
- Government of Canada
- University of Nottingham
- City of Hope National Medical Center
- Mundipharma
- Institut Bergonié
- Russian Academy of Medical Sciences
- Tianjin Medical University
- +93 more
Organization Involved with Phase 2 Indications (330)
- Hôpital Maisonneuve Rosemont, Montréal, QC, Canada
- Universidad Autonoma de Barcelona
- University of California, San Diego
- Temple University
- Georgetown University
- Plexxikon
- Hospital Universitario Central de Asturias
- University of Roma La Sapienza
- CureTech Ltd
- PDL BioPharma
- Cytokinetics
- French National Agency for Research on AIDS and Viral Hepatitis
- Technion University
- Eisai
- Badalona Hospital Germans Trias i Pujol
- University of Antwerp
- National University of Singapore
- Human Genome Sciences
- University of Southern California
- St. John Hospital and Medical Center, Van Elslander Cancer Center
- University of Alabama, Birmingham
- Vical
- Fundación Leucemia y Linfoma, Spain
- JSS Medical Research Inc.
- University of Leeds
- Immune Design
- Sirna Therapeutics
- University of Valencia
- Sinocelltech Ltd.
- University of Medicine and Dentistry of New Jersey
- +300 more
Organization Involved with Phase 1 Indications (112)
- Shenzhen University
- ShangHai HaiHe Pharmaceutical
- Aptevo Therapeutics
- Regimmune Inc.
- Biotec Pharmacon ASA
- Ono Pharmaceuticals
- Applied Molecular Evolution
- Nevada Cancer Institute
- Hospital Regional De Concepción
- Thywill Latam Solutions SRL
- Fundación Centro Oncológico de Integración Regional - COIR.
- Celator Pharmaceuticals
- LAM Therapeutics Inc.
- Janssen Pharmaceutica NV
- ADC Therapeutics SARL
- Caribou Biosciences
- Hebei Senlang Biotechnology Inc., Ltd.
- University of Nantes
- Chongqing Medical University
- Oncotartis, Inc.
- Guizhou Medical University
- IGM Biosciences, Inc.
- Morphotek
- MingJu Therapeutics
- Aptose Biosciences Inc.
- Yale University
- Menarini Group
- Hainan People's Hospital
- Shanghai Longyao Biotechnology Inc., Ltd.
- Infinity Pharmaceuticals, Inc.
- +82 more
Organization Involved with Other Experimental Indications (11)